Newbury Pharmaceuticals announced the Marketing Authorization of Dimethyl Fumarate Newbury 120 & 240 mg hard capsule in Sweden as the first country in a Scandinavian registration procedure. Approvals in Norway and Denmark are expected to follow upon finalized national reviews. Dimethyl Fumarate Newbury is indicated for the treatment of relapsing remitting multiple sclerosis.

The product has been developed based on the reference brand Tecfidera. MS is a disease of the nerves, in which inflammation destroys the protective sheath around the nerves. Multiple sclerosis is characterized by immune-mediated inflammation and neurodegeneration.

It is a disease of unknown etiology.